These melanogenesis studies established MT-1 as the most pharmacologically tractable reference agonist for MC1R-mediated pigmentation biology and provided the foundational characterisation of the MC1R-cAMP-MITF-tyrosinase signalling cascade
Regulatory Status and FDA Approval Timeline Current FDA Status (as of June 2026) The FDA has not approved retatrutide for any indication as of June 2026
This does not prevent the delayed reaction, but it eliminates the immediate sting, which for many people is the trigger for injection anxiety
Increased urination accompanied by the following symptoms may indicate inadequate diabetes control: Excessive thirst (polydipsia) : The combination of increased urination and persistent thirst suggests hyperglycaemia Unexplained weight loss : Despite Ozempic's weight-reducing effects, rapid or excessive weight loss with increased urination may indicate poor glycaemic control Fatigue and blurred vision : These symptoms alongside polyuria suggest elevated blood glucose levels Fruity-smelling breath : This may indicate diabetic ketoacidosis, a medical emergency requiring immediate attention - call 999 or go to A&E Other concerning presentations include: Urinary tract infection (UTI) : Increased frequency accompanied by burning sensation, cloudy or strong-smelling urine, lower abdominal pain, or fever requires prompt medical assessment
Minor bruising is completely normal after semaglutide injections and does not indicate improper technique or medication failure
